Health ❯ Healthcare ❯ Pharmaceuticals

Side Effects

Adverse Reactions Gastrointestinal Issues Drug Safety Gastrointestinal Effects Nausea and Vomiting Medication Risks Ozempic Teeth Rare Adverse Effects Clinical Study Results Adverse Events

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

The move positions Lilly to challenge Novo Nordisk by pairing a more flexible pill with a rapid LillyDirect rollout and aggressive self-pay pricing.

Lilly’s Triple-Agonist Retatrutid Delivers About 29% Weight Loss in Phase 3, with Notable Side Effects

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

Stiftung Warentest Says Most Cough Medicines Aren’t Worth the Money

FDA Approves Lilly’s Inluriyo for ESR1‑Mutated Advanced Breast Cancer

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

EU Mandates New Warning on Systemic Diclofenac Skin Reaction

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

Novo Nordisk’s Amycretin Delivers Up to 24% Early Weight Loss in Dual-Form Trials

‘Ozempic Teeth’ Emerges as a Serious Dental Risk for Weight-Loss Drug Users

Leqembi Approved by European Regulators for Early-Stage Alzheimer's Treatment

Clonazepam Recalled Nationwide Over Potentially Life-Threatening Labeling Error

Novo Nordisk's Obesity Pill Shows Modest Results, Stocks Drop

Oxford Study Identifies Most Effective Migraine Treatments

Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial